Halozyme Therapeutics (HALO)
收市後：
| 前收市價 | 39.30 |
| 開市 | 39.56 |
| 買盤 | 39.80 x 200 |
| 賣出價 | 39.87 x 200 |
| 今日波幅 | 38.88 - 40.41 |
| 52 週波幅 | 29.85 - 45.00 |
| 成交量 | |
| 平均成交量 | 1,005,014 |
| 市值 | 5.059B |
| Beta 值 (5 年，每月) | 1.25 |
| 市盈率 (最近 12 個月) | 18.96 |
| 每股盈利 (最近 12 個月) | 2.10 |
| 業績公佈日 | 2024年5月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 51.11 |
ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
InvestorPlace3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
If you have a high tolerance for volatility then the biotech sector might be for you. Biotech stocks can range from pre-revenue startups to global pharmaceutical giants. All it takes is one treatment to put the company on the map and provide outsized returns for its shareholders. Biotech is one of those growth sectors that have the potential to provide multibagger returns to your portfolio. Many fortunes have been made with a fortuitous investment in a Biotech stock at the right time. That time
ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
